"Obesity - Pipeline Review, H1 2014" Is Now Available at Fast Market Research

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Logo

Boston, MA -- (ReleaseWire) -- 05/14/2014 --Obesity - Pipeline Review, H1 2014

Summary

Global Markets Direct's, 'Obesity - Pipeline Review, H1 2014', provides an overview of the Obesity's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Obesity, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Obesity and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Obesity
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Obesity and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Obesity products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Obesity pipeline on the basis of target, MoA, route of administration and molecule type

Companies Mentioned in this Report: F. Hoffmann-La Roche Ltd., Shionogi & Co., Ltd., Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, Athersys, Inc., GlaxoSmithKline plc, Isis Pharmaceuticals, Inc., Merck & Co., Inc., Dainippon Sumitomo Pharma Co., Ltd., Euroscreen S.A., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Plexxikon Inc., Ipsen S.A., CARDIONOVA LTD., Chong Kun Dang Pharmaceutical Corp., GTx, Inc., Kissei Pharmaceutical Co., Ltd., LEO Pharma A/S, Pfizer Inc., Vivus, Inc., Zydus Cadila Healthcare Limited, OPKO Health, Inc., Genfit SA, Arrowhead Research Corporation, Ligand Pharmaceuticals, Inc., Calzada Limited, NeuroSearch A/S, Orchid Chemicals & Pharmaceuticals Ltd, Arena Pharmaceuticals, Inc., WhanIn Pharmaceutical Co., Ltd., Handok Inc., Hyundai Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Transition Therapeutics Inc., Suven Life Sciences Ltd., Galapagos NV, Phynova Group Ltd, Orexigen Therapeutics, Inc., DiaMedica Inc., NeuroVive Pharmaceutical AB, Digna Biotech, S.L., Advinus Therapeutics Ltd., Betagenon AB, Aurigene Discovery Technologies Limited, Jenrin Discovery, Inc., Upsher-Smith Laboratories, Inc., ObeTherapy Biotechnology, Helsinn Healthcare S.A., Xenon Pharmaceuticals Inc., Spherix Incorporated, Ocera Therapeutics, Inc., AngioChem Inc., Kedem Pharmaceuticals Inc., Zafgen Inc., Ambrx, Inc., Braasch Biotech LLC, Zealand Pharma A/S, Indus Biotech Private Limited, Intarcia Therapeutics, Inc., Thrasos, Inc., Versartis, Inc., Kainos Medicine, Inc., Nordic Bioscience a/s, Avaxia Biologics, Inc., Omeros Corporation, Aegis Therapeutics, LLC, Bridge Bioresearch Plc, Synthetic Biologics, Inc., Globeimmune, Inc., Targacept, Inc., Molecular Design International, Inc., N-Gene Research Laboratories, Inc., Seek, Vitae Pharmaceuticals, Inc., Galenea Corp., Verva Pharmaceuticals Limited, Regulus Therapeutics Inc., Esperion Therapeutics, Inc., Sorrento Therapeutics, Inc., Domainex Ltd., Alize Pharma SAS, DiscoveryBiomed, Inc., Mitsubishi Pharmaceutical Corporation, Sirona Biochem Corp, Vicore Pharma AB, Carmot Therapeutics, Inc., Reviva Pharmaceuticals Inc., PharmaIN Corporation, Rhythm Pharmaceuticals, Selvita S.A, Kadmon Pharmaceuticals, LLC, Shanghai Pharmaceuticals Holding Co Ltd, Hanmi Pharmaceuticals, Co. Ltd., X-BODY BioSciences, Inc., Lead Discovery Center GmbH, Adial Pharmaceuticals, LLC, P2D Bioscience, High Point Pharmaceuticals, LLC, Arrien Pharmaceuticals, LLC, Chronos Therapeutics Limited, nLife Therapeutics, S.L., XL-protein GmbH, Akron Molecules GmbH

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Depression - Pipeline Review, H1 2014
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2014
- Metastatic Breast Cancer - Pipeline Review, H1 2014
- Breast Cancer - Pipeline Review, H1 2014
- Multiple Myeloma (Kahler's Disease) - Pipeline Review, H1 2014
- Multiple Sclerosis - Pipeline Review, H1 2014
- Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014
- Non-Small Cell Lung Cancer - Pipeline Review, H1 2014
- Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014
- Cognitive Impairment - Pipeline Review, H1 2014

Media Relations Contact

Bill Thompson
Director of Marketing
Fast Market Research, Inc.
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/505510